Lack of correlation between elevated maternal serum hCG during second‐trimester biochemical screening and fetal congenital anomaly

Celentano, Claudio; Guanciali-Franchi, Paolo; Liberati, Marco; Palka, Chiara; Fantasia, Donatella; Morizio, Elisena; Calabrese, Giuseppe; Stuppia, Liborio; Rotmensch, Siegfried

doi:10.1002/pd.1110

Cited by 2 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increased incidence of structural abnormalities was reported to be associated with elevated mid-trimester levels of hCG (Fejgin et al, 1997). Another study by Celentano et al (2005) indicated a lack of correlation between elevated maternal serum hCG and fetal congenital anomalies. The current study represents the largest, most comprehensive analysis of the association of screen-positive status and secondtrimester ultrasound findings to date.…”

Section: Discussionmentioning

confidence: 95%

Ancillary benefits of prenatal maternal serum screening achieved in the California program

et al. 2010

View full text Add to dashboard Cite

Objective To evaluate the extent of fetal structural abnormalities, other than neural tube and abdominal wall defects (AWDs), identified by California's Prenatal Screening Program. MethodsThe Quad Marker Prenatal Screening records of 516,172 women were examined for screening interpretation and the diagnosis of structural abnormalities detected via follow-up. Women who were screenpositive for trisomy 21, trisomy 18, neural tube defects (NTDs) or Smith-Lemli-Opitz syndrome (SLOS) received follow-up services at state-approved Prenatal Diagnosis Centers (PDCs). Detailed reports of services and diagnostic information were linked in a database to the original screening results.Results A total of 26 323 women received follow-up ultrasound services at the PDCs in the study time period. Of these women, 1085 (4.1%) were identified as having fetuses with significant structural abnormalities, other than NTDs (n = 207) or AWDs (n = 254). In addition to the structural abnormalities, 225 cases of fetal demise, 4 molar pregnancies, 15 cases of twin-to-twin transfusion, and 92 cases with placental abnormalities were identified. ConclusionWhile Prenatal Screening Programs do not explicitly screen for structural abnormalities other than NTDs and AWDs, clearly many other structural abnormalities may be associated with a screen-positive status. Thus, the detection of these additional structural defects can be considered an ancillary program benefit.

show abstract

Section: Discussionmentioning

confidence: 95%

Ancillary benefits of prenatal maternal serum screening achieved in the California program

et al. 2010

View full text Add to dashboard Cite

show abstract

“…More recently, associations between abnormal levels of maternal serum markers and single gene disorders, such as Smith-Lemli-Opitz and Cornelia de Lange, have been found (Canick et al ., 1997; Aitken et al ., 1999; Palomaki et al ., 2002; Craig et al ., 2006). Few studies to date have examined the possibility of using maternal serum screening results to detect common congenital anomalies or single gene disorders other than those that are mentioned above (Celentano et al, 2005). …”

Section: Introductionmentioning

confidence: 99%

Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two‐vessel cord, and hydrocele

et al. 2008

View full text Add to dashboard Cite

Objective-The FASTER trial compared 1 st and 2 nd trimester screening methods for aneuploidy. We examined relationships between maternal serum markers and common congenital anomalies in the pediatric outcome data set of 36,837 subjects.Methods-We used nested case control studies, with cases defined by the most common anomalies in our follow-up database, and up to four controls matched by enrollment site, maternal age and race, enrollment gestational age, and infant gender. Serum markers were dichotomized to ≥ 2 or < 0.5 multiples of the median (MoM). Odds ratios and 95% confidence intervals (C.I.) were estimated.Results-Statistically significant (p < 0.05) associations were found between inhibin A ≥ 2 MoM and fetal multicystic dysplastic kidney (MCDK) (odds ratio (OR) =27.5, 95% C.I.:

show abstract

Lack of correlation between elevated maternal serum hCG during second‐trimester biochemical screening and fetal congenital anomaly

Cited by 2 publications

References 35 publications

Ancillary benefits of prenatal maternal serum screening achieved in the California program

Ancillary benefits of prenatal maternal serum screening achieved in the California program

Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two‐vessel cord, and hydrocele

Contact Info

Product

Resources

About